Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey
-
- Oguma Tsuyoshi
- Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine
-
- Taniguchi Masami
- Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital
-
- Shimoda Terufumi
- Clinical Research Center, Fukuoka National Hospital
-
- Kamei Katsuhiko
- Division of Clinical Research, Medical Mycology Research Center, Chiba University
-
- Matsuse Hiroto
- Division of Respirology, Department of Internal Medicine, Toho University Ohashi Medical Center
-
- Hebisawa Akira
- Clinical Research Center, Tokyo National Hospital
-
- Takayanagi Noboru
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center
-
- Konno Satoshi
- First Department of Medicine, Hokkaido University Graduate School of Medicine
-
- Fukunaga Koichi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
-
- Harada Kazuki
- Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine
-
- Tanaka Jun
- Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine
-
- Tomomatsu Katsuyoshi
- Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine
-
- Asano Koichiro
- Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine
この論文をさがす
抄録
<p>Background: Allergic bronchopulmonary aspergillosis (ABPA) is an allergic pulmonary disease characterized by a hypersensitivity reaction to Aspergillus species colonizing the airways. The clinical characteristics of ABPA may differ depending on genetic and environmental background. We performed a nationwide survey to determine the clinical characteristics of ABPA in Japan.</p><p>Methods: In 2013, a questionnaire on physician-diagnosed ABPA/allergic bronchopulmonary mycosis was sent to 903 medical centers specializing in respiratory or allergic diseases. Cases fulfilling the following criteria were categorized as possible ABPA-central bronchiectasis (ABPA-CB): 1) presence of specific serum immunoglobulin E (IgE) antibodies or a positive skin reaction to Aspergillus, and 2) bronchiectasis or mucoid impaction in the central bronchi.</p><p>Results: Of 499 physician-diagnosed cases reported by 132 clinical centers, 358 cases met the criteria for possible ABPA-CB. Median age of ABPA-CB onset was 57 (interquartile range, 44-68) years; later-onset disease, developing ≥50 years of age, accounted for 66% of the cases and was associated with female sex, delayed onset of asthma, and lower levels of serum IgE. A third of the patients (120 patients, 34%) exhibited low levels of serum total IgE (<1000 IU/mL). Aspergillus species were isolated from sputum in 126/213 cases (59%), and Schizophyllum commune was identified in 12 (6%) patients. During the course of the treatment, ABPA recurred in 169 (48%) cases.</p><p>Conclusions: This nationwide survey identified several unique clinical characteristics of ABPA in Japan, such as late-onset, relatively lower serum IgE levels, and frequent recurrences/flares.</p>
収録刊行物
-
- Allergology International
-
Allergology International 67 (1), 79-84, 2018
一般社団法人日本アレルギー学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390001204632841344
-
- NII論文ID
- 130006322061
-
- ISSN
- 14401592
- 13238930
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可